- Info
- Portfolio
- Significant Ownership
- Insider Ownership
Significant Ownership of ORBIMED ADVISORS LLC
- Signature - Title
- /s/ Carl L. Gordon - Carl L. Gordon/Member
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by ORBIMED ADVISORS LLC.
Follow Filing Activity
Follow ORBIMED ADVISORS LLC and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of ORBIMED ADVISORS LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| TRAW | Traws Pharma, Inc. | Common Stock | 20% | $1,164,061 | 760,824 | ORBIMED ADVISORS LLC | 31 Dec 2024 | ||
| QTTB | Q32 Bio Inc. | COMMON STOCK | 15% | $8,628,940 | 2,252,987 | ORBIMED ADVISORS LLC | 18 Feb 2026 | ||
| EWTX | Edgewise Therapeutics, Inc. | Common Stock | 14% | $234,894,152 | 15,252,867 | ORBIMED ADVISORS LLC | 09 May 2025 | ||
| ELVN | Enliven Therapeutics, Inc. | COMMON STOCK | 13% | $140,468,212 | 7,918,163 | ORBIMED ADVISORS LLC | 16 Jun 2025 | ||
| CRVS | CORVUS PHARMACEUTICALS, INC. | COMMON STOCK | 10% | $66,290,001 | -$9,057,756 | 8,609,091 | -12% | ORBIMED ADVISORS LLC | 23 Jan 2026 |
| STTK | Shattuck Labs, Inc. | Common Stock, par value $0.0001 per share | 10% | $5,107,963 | 6,306,127 | ORBIMED ADVISORS LLC | 25 Aug 2025 | ||
| ACET | Adicet Bio, Inc. | Common Stock, par value $0.0001 | 9.6% | $11,974,668 | 14,772,598 | ORBIMED ADVISORS LLC | 08 Oct 2025 | ||
| CMPX | Compass Therapeutics, Inc. | COMMON STOCK | 8.9% | $41,093,984 | 15,219,994 | 0% | ORBIMED ADVISORS LLC | 13 Aug 2025 | |
| WHWK | Whitehawk Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 8.9% | $6,415,640 | 4,166,000 | OrbiMed Advisors LLC | 31 Mar 2025 | ||
| SION | Sionna Therapeutics, Inc. | Common Stock | 8.4% | $44,607,706 | 3,704,959 | ORBIMED ADVISORS LLC | 10 Feb 2025 | ||
| NPCE | NeuroPace Inc | Common Stock, par value $0.001 per share | 8% | $26,716,960 | -$8,095,783 | 2,614,184 | -23% | OrbiMed Advisors LLC | 30 Jun 2025 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 8% | $3,763,800 | 510,000 | ORBIMED ADVISORS LLC | 31 Dec 2024 | ||
| MBX | MBX Biosciences, Inc. | COMMON STOCK | 7.7% | $118,413,222 | -$11,880,750 | 3,637,887 | -9.1% | ORBIMED ADVISORS LLC | 05 Feb 2026 |
| AVBP | ArriVent BioPharma, Inc. | Common Stock | 7.5% | $66,692,036 | 3,027,328 | ORBIMED ADVISORS LLC | 11 Aug 2025 | ||
| NSPR | InspireMD, Inc. | Common Stock, par value $0.0001 per share | 7.4% | $5,577,461 | +$1,780,000 | 3,133,405 | +47% | ORBIMED ADVISORS LLC | 31 Dec 2025 |
| IKNA | ImageneBio, Inc. | COMMON STOCK | 6.9% | $820,179 | -$7,669,269 | 773,754 | -90% | ORBIMED ADVISORS LLC | 25 Jul 2025 |
| RAPT | RAPT Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 6.6% | $28,023,878 | -$310,734,477 | 1,086,618 | -92% | ORBIMED ADVISORS LLC | 30 Sep 2025 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, par value $0.001 per share | 6.4% | $20,124,735 | +$3,734,085 | 1,187,300 | +23% | OrbiMed Advisors LLC | 31 Dec 2025 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | Common Stock, par value $0.0001 per share | 5.9% | $5,307,498 | 718,200 | OrbiMed Capital LLC | 31 Dec 2024 | ||
| CYBN | Cybin Inc. | Common Stock, no par value | 4.9% | 2,422,600 | ORBIMED CAPITAL LLC | 31 Dec 2025 | |||
| TERN | Terns Pharmaceuticals, Inc. | Common Stock | 4.8% | $31,842,911 | 4,240,068 | ORBIMED ADVISORS LLC | 03 Nov 2025 | ||
| IRON | Disc Medicine, Inc. | Common Stock | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | ||
| PASG | Passage BIO, Inc. | COMMON STOCK | 4.2% | $53,029 | -$44,595 | 132,473 | -46% | ORBIMED ADVISORS LLC | 22 Jul 2025 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.2% | $1,213,378 | 1,639,700 | 0% | ORBIMED CAPITAL LLC | 31 Dec 2025 | |
| ADCT | ADC Therapeutics SA | Common Shares, par value CHF 0.08 per share | 2.6% | $11,953,949 | -$765,959 | 3,230,797 | -6% | ORBIMED CAPITAL LLC | 31 Dec 2025 |
| VSTM | Verastem, Inc. | Common Stock, par value $0.0001 per share | 2.4% | $6,319,998 | -$7,248,005 | 1,333,333 | -53% | ORBIMED ADVISORS LLC | 30 Jun 2025 |
| CTMX | CytomX Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 2.1% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| XFOR | X4 Pharmaceuticals, Inc | Common Stock, par value $0.001 per share | 1.7% | $25,640 | 134,947 | ORBIMED ADVISORS LLC | 30 Jun 2025 | ||
| CCCC | C4 Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 1% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
| XTNT | Xtant Medical Holdings, Inc. | COMMON STOCK | 0% | $0 | 0 | ORBIMED ADVISORS LLC | 10 Apr 2025 | ||
| PMVP | PMV Pharmaceuticals, Inc. | COMMON STOCK | 0% | $0 | -$6,219,114 | 0 | -100% | ORBIMED ADVISORS LLC | 02 Mar 2026 |
Schedules 13D/G Reported by ORBIMED ADVISORS LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.